Transcriptome profiling of human myogenic progenitors following treatment with nicotinamide (NAM) or pyridoxine (PN) or the combination (NAM/PN).

Working with primary human myogenic progenitors (hMPs), we developed a high-content screen to discover molecules that enhanced myogenic function and identified NAM and PN as modulators of myogenic proliferation and differentiation. We characterized genome-wide expression profiles of NAM-, PN-treated and NAM/PN-treated hMPs with the goal to uncover the mechanisms of action of NAM and PN and the potential additivity from the combination at the molecular level in hMPs. Overall design: hMPs (commercially available from Lonza) were treated with either 1% DMSO (vehicle), 1mM of nicotinamide, or 1mM of pyridoxine or the combination for 72 hours in growth medium (AmsBio). We performed biological replicates on 5 different donors for each treatment condition.